Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe Who Have Received at Least One Prior Therapy

Next Previous
X
Search
Trial Profile

Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe Who Have Received at Least One Prior Therapy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carfilzomib (Primary) ; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Amgen

    • Most Recent Events

    • 17 Jun 2021 Results (n=144) assessing effectiveness, safety and usage of K-based regimens across four countries Bulgaria, Czech Republic, Israel, Romania during this trial presented at the 26th Congress of the European Haematology Association
    • 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
    • 08 Dec 2020 Results (n=655; as of 17 Mar 2020) presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top